A water soluble FRET-based ratiometric chemosensor for Hg(ii) and S2−applicable in living cell staining

RSC Advances ◽  
2014 ◽  
Vol 4 (29) ◽  
pp. 14919-14927 ◽  
Author(s):  
Buddhadeb Sen ◽  
Manjira Mukherjee ◽  
Siddhartha Pal ◽  
Koushik Dhara ◽  
Sushil Kumar Mandal ◽  
...  

A new water soluble rhodamine-based ratiometric dual ‘off–on–off’ probe can selectively detect Hg2+ions in ppb level through time dependent FRET process with reversibility in presence of S2−anions.

2013 ◽  
Vol 5 (1) ◽  
pp. 169-172 ◽  
Author(s):  
Debasis Karak ◽  
Arnab Banerjee ◽  
Sisir Lohar ◽  
Animesh Sahana ◽  
Subhra Kanti Mukhopadhyay ◽  
...  

2019 ◽  
Vol 43 (7) ◽  
pp. 3169-3173 ◽  
Author(s):  
Haiyuan Ding ◽  
Gangqiang Yuan ◽  
Liyi Zhou

Benzoyl peroxide (BPO), a member of small-molecule reactive oxygen species (ROS), has attracted considerable attention because of its impact on human health and industrial importance.


The Analyst ◽  
2012 ◽  
Vol 137 (17) ◽  
pp. 3910 ◽  
Author(s):  
Animesh Sahana ◽  
Arnab Banerjee ◽  
Sisir Lohar ◽  
Subarna Guha ◽  
Sudipta Das ◽  
...  

Polymer ◽  
2016 ◽  
Vol 82 ◽  
pp. 172-180 ◽  
Author(s):  
Liang Wang ◽  
Chen Sun ◽  
Shuofeng Li ◽  
Ning Jia ◽  
Jian Li ◽  
...  

2014 ◽  
Vol 50 (3) ◽  
pp. 535-541 ◽  
Author(s):  
Meijuan Zou ◽  
Caixia Wang ◽  
Xuezhu Zhang ◽  
Tao Xu ◽  
Jiarong Han ◽  
...  

Our research has focused on the main design features and release performances of time-dependent colon-specific (TDCS) delivery tablets, which relies on the relative constancy that is observed in the small intestinal transit time of dosage forms. But inflammatory bowel disease(IBD)can affect the transit time, and usually results in watery stool. Compared to the TDCS and wax-matrix TDCS tablet, a promising time-dependent colon-specific delivery system was investigated. In our study, a suppository-base-matrix coated tablet was evaluated. Water soluble suppository-base helps the expansion of tablet, facilitates uniform film dissolution and achives high osmotic pressure. Combining the expansion of carboxymethyl starch sodium (CMS-Na) and the moisture absorption of NaCl, the coated TDCS tablet obtained a burst and targeted drug delivery system. A very good correlation between in vitro drug release and in vivo outcome was observed. This TDCS coated tablet provides a promising strategy to control drug release to the desired lower gastrointestinal region.


1990 ◽  
Vol 36 (124) ◽  
pp. 287-298 ◽  
Author(s):  
Neil Humphrey ◽  
Keith Echelmeyer

AbstractDrilling bore holes in deep, cold ice masses by hot-water methods and maintaining these holes with sufficient diameter to allow down-hole experimentation poses a major obstacle to the investigation of conditions beneath ice sheets and ice streams. Closure of the water-filled holes by refreezing is the dominant difficulty. In this paper, we describe calculations of heat transfer from the drilling system to the ice and the subsequent time-dependent motion of the phase boundary defining the bore-hole wall. Results are presented with the view of optimizing the bore-hole radius at depth for a fixed drill performance and a variable rate of drilling.Calculation of melting/refreezing rates at the bore-hole wall requires the use of a one-dimensional, time-dependent numerical heat-flow model with a distorting mesh which follows the changing hole size. The delay of hole closure is discussed with a view to keeping holes open long enough to allow instruments to be lowered to the glacier bed, while realizing that drilling-system performance may be marginal because of logisitical and/or expenditure constraints. The relative merits of drilling a large hole, which is very time consuming with a small drill, and the use of water-soluble antifreezes, which have a history of creating plugs of ice slush, are discussed. A method of creating a stable hole filled with antifreeze in which ice slush does not occur is described.The recent application of these theoretical ideas to the planning and implementation of successful hot-water drilling programs in Antarctica and Greenland is also presented.


2021 ◽  
Vol 16 (2) ◽  
pp. 1-11
Author(s):  
A. A. Abdullahi ◽  
B. A. Aremu ◽  
S. A. Atunwa ◽  
S. O. Usman ◽  
F.A.U. Attah ◽  
...  

Background: ChromolaenaodorataLinn. (Asteraceae)is being used traditionally for its many medicinal properties including lowering of blood glucose level. However, few and inconsistent information about its antidiabetic potential is available.Objective: to standardize; determine physicochemical and elemental parameters; and evaluate anti-diabetic potential of Chromolaena odorata Linn. (Asteraceae) powdered leaves in alloxan-induced diabetic rats.Materials and Methods: Physicochemical screening of fresh and powdered leaves of C. odorata leaves were respectively determined using a light microscope connected to a standard camera. Elemental analysis was done using Atomic Absorption Spectrometer (AAS) GBC Avanta Model. Thirty-three Wistar rats of either sex weighing 150 – 200 g were used in the procedures. Acute toxicity assessment (LD50) was carried out using the guideline of Organization for Economic Cooperation and Development (OECD). Chromolaena odorata powdered leaves were evaluated using alloxan-induced model.Results: Physicochemical screening of the fresh and powdered leaves confirmed the pharmacognostic parameters of Chromolaena odorata. The moisture content was 6.0 ± 0.07 %, the alcohol soluble extractive was 30 ± 0.05 %. while the water-soluble extractive was 40 ± 0.05%. The elemental analysis of the powdered leaves of C. odorata showed that the leaves contains 29.00mg/L of K, 13.500mg/L of Na, 0.15mg/L of Mn, 4.78mg/L of Mg and 0.30mg/L of Ca. Chromolaena odorata showed no toxicity when it was orally administered to rats (LD50 ≥ 2000 mg/kg). The powdered leaves of Chromolaena odorata at 100, 200 and 300 mg/kg showed dose and time-dependent anti-diabetic activities.Conclusion: The powdered leaves of Chromolaena odorata is non-toxic and preliminary data showed its anti-diabetic potential possibly due to the presence of some phytochemicals and mineral elements identified  


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4446-4446 ◽  
Author(s):  
Taghi Manshouri ◽  
Subbarao V. Kala ◽  
Faramarz Ashoori ◽  
Ralph Zingaro ◽  
Emil J. Freireich ◽  
...  

Abstract Arsenic trioxide (As2O3; ATO) inhibits proliferation and induces apoptosis of APL cells. However, little is known about the intracellular structural changes associated with arsenic exposure. We studied effects of 2 arsenic compounds, ATO and S-dimethylarsino-glutathione (SGLU; ZIO-101) on NB4 APL cells. ZIO-101 is novel water-soluble organic arsenic derivative currently in Phase I clinical studies. Exposure of cancer cells to ZIO-101 results in G2/M cell cycle arrest and apoptosis. NB4 cells were exposed to 10, 50, 100 and 250 μM ZIO-101 or ATO for 1 h and intracellular arsenic content was determined by inductively coupled plasma mass spectrometry (ICP/MS). ZIO-101-treated cells contained 5–8 fold more arsenic then ATO-treated cells. Electron microscopy of NB4 cells exposed to 1 μM ZIO-101 or ATO for 24–72 h revealed different structural changes. ATO treated cells showed time-dependent mitochondrial hypotrophy and apoptosis, including cytoplasmic vacuolization, nuclear condensation and cell blebs. In contrast, ZIO-101 treated cells showed time-dependent mitochondrial atrophy, mitochondrial matrix condensation, and apoptosis. These data suggest that ZIO-101 is more specific mitochondrial toxin than ATO. Studies are in progress to understand the exact mechanism through which ZIO-101 affects mitochondria. Because these arsenic derivatives have different mechanism of action they may have different spectrums of activity against cancers; this should be tested in clinical trials.


2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21660-e21660
Author(s):  
Aditya Kulkarni ◽  
Aulma Parker ◽  
Kamwing Jair ◽  
Pavankumar Petluru ◽  
Xinghai Chen ◽  
...  

e21660 Background: Lung cancer in non-smokers (LCINS) is the seventh leading cause of death among solid tumors. LCINS is more frequent in women, and the histological incidence of adenocarcinoma is higher among non-smokers. The mutation pattern by smoking status in non-small cell lung cancer (NSCLC) is distinct with genomic alterations in EGFR, MET and ROS1 being more frequent in non-smokers. Non-smoking status is the strongest clinical predictor of benefit from the EGFR TKIs. Lantern Pharma is developing LP-300/Dimesna, a non-toxic, well-tolerated, water-soluble disulfide as a combination therapy agent potentially indicated in female never-smokers with adenocarcinoma. Retrospective subgroup analyses of prior phase 3 trial data showed substantial overall survival benefit for LP-300 in combination with standard chemotherapy in patients with advanced NSCLC, especially in the female non-smoker adenocarcinoma subgroup (13.4 months in control arm to 27 months in treatment arm). Purpose of this work conducted at BioNumerik Pharmaceuticals was to determine if LP-300 modulates activity of selected receptor tyrosine kinases relevant to non-smoker NSCLC. Methods: In vitro luminescence-based kinase assays were used to evaluate the effect of LP-300 and LP-300-derived mesna-disulfide heteroconjugates, Erlotinib, and Crizotinib, in combination and as single agents, on EGFR, MET, and ROS1 kinase activity. Results: LP-300 inhibited WT EGFR kinase and MET kinase. LP-300 had a time-dependent inhibitory effect on ROS1 kinase activity. LP-300 and LP-300-derived mesna-disulfide heteroconjugates stimulated Erlotinib-mediated inhibition of WT and T790M EGFR. T790M EGFR is normally insensitive to Erlotinib but when LP-300 was used with Erlotinib, inhibition was more prominent. LP-300 also stimulated Crizotinib-mediated inhibition of MET kinase and displayed time-dependent stimulation of Crizotinib-mediated inhibition of ROS1 kinase. Conclusions: LP-300 is a multi-targeted modulator of enzymatic activities of EGFR, MET and ROS1, and potentiates the activity of Erlotinib and Crizotinib. EGFR family members contain conserved extracellular structures that are stabilized by disulfide bonds. Compounds that disrupt extracellular disulfide bonds could inactivate EGFR and potentially downregulate EGFR-dependent proliferative signaling in cancer cells. We propose LP-300 as a Disulfide Bond Disrupting Agent (DDA) that may complement existing EGFR-targeted agents functioning through alternate mechanisms.


Sign in / Sign up

Export Citation Format

Share Document